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Abstract
Background: Minimally invasive vertebral augmentation procedures are widely used to treat vertebral compression
fractures although procedural polymethylmethacrylate cement leakage remains common. We report herein our
initial experience with a novel vertebral augmentation technique designed to treat symptomatic vertebral
osteoporotic fractures and osteolytic metastases with minimal cement extravasation.
Methods: Forty-two vertebral fractures were identified in 26 consecutive patients (mean age 74 ± 9 years). All
patients were treated with a novel percutaneous vertebral augmentation device (Kiva
® VCF Treatment System,
Benvenue Medical, Santa Clara, CA, USA). Indications for surgery included recent (≤ 3 months) symptomatic
osteoporotic vertebral fracture (n = 34) and pathologic vertebral fractures (e.g. metabolic bone disease, myeloma,
metastasis) (n = 8) located between T10 and S1. Patient outcomes were evaluated pre-treatment and at 2- and 6-
month follow-up visits. Postoperative cement extravasation was assessed with computed tomography. Patient-
reported back pain was quantified using an 11-point numeric scale. Back-specific functional disability was self-
reported with the Oswestry Disability Index on a 0 to 100% scale.
Results: No cases of intraoperative hypotension, respiratory disturbance, neurological deterioration, infection, or
death were observed. There were 2 (4.8%) levels where anterior cement leakage was visible radiographically in
patients with osteolyses. No intracanal leakage was observed. Back pain scores improved 71% (p < 0.001) from pre-
treatment to the 6-month follow-up. Back function improved 56% from baseline to 6 months (p < 0.001).
Conclusions: The initial clinical experience with the Kiva
® System demonstrated significant improvements in back
pain and function with minimal and clinically insignificant procedural cement leakage.
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Background
Vertebral compression fractures are common injuries
with an incidence of 1.4 million each year [1]. Manifes-
tations of fractured vertebrae include severe chronic
back pain, disability, and reductions in quality of life
[2-7] as well as greater risk for future vertebral frac-
tures [8]. Acute, symptomatic vertebral compression
fractures are initially treated with conservative care,
which may include bed rest, bracing, analgesic medica-
tion, and/or physical rehabilitation and exercise pro-
grams. However, vertebral deformity and back pain
often persist despite these measures and, therefore,
surgery may eventually be required [9]. Minimally
invasive vertebral augmentation procedures have been
widely used to treat vertebral compression fractures
caused by osteoporosis and, less commonly, osteolytic
tumors [10-16]. Although the results of these trials are
encouraging, procedural polymethylmethacrylate
(PMMA) cement leakage remains common with a fre-
quency of 7% to 72% per treated level [10,17-20]. We
* Correspondence: jonblock@jonblockphd.com
3Jon E. Block, PhD, Inc., 2210 Jackson Street, Suite 401, San Francisco, CA
94115 USA
Full list of author information is available at the end of the article
Korovessis et al. BMC Musculoskeletal Disorders 2011, 12:206
http://www.biomedcentral.com/1471-2474/12/206
© 2011 Korovessis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.report herein our initial experience with a novel ver-
tebral augmentation system designed to treat painful
vertebral osteoporotic fractures and osteolytic metas-
tases with minimal cement extravasation.
Methods
Patients
This single-arm, feasibility trial was conducted at the
first author’s institution between January 2010 and April
2010. All study procedures were conducted in accor-
dance with the ethical principles stated in the Declara-
tion of Helsinki and this research was approved by the
General Hospital “Agios Andreas” (Patras, Greece).
Forty-two vertebral augmentation procedures were per-
formed in 26 consecutive patients (mean age 74 ± 9
years; range: 58 to 86 years). Indications for surgery
included recent (≤ 3 months) symptomatic osteoporotic
vertebral fracture (n = 34) and pathologic vertebral frac-
tures (e.g. metabolic bone disease, myeloma, metastasis)
(n = 8) located between T10 and S1. Symptomatic levels
were confirmed with x-ray, computed tomography, and/
or magnetic resonance imaging.
Interventions
The procedures were performed with the patient under
general anesthesia and placed in the prone position on
an AcroMed frame (DePuy Spine, Inc., Raynham, MA,
USA). All patients were treated with a novel percuta-
neous vertebral augmentation device (Kiva
® VCF
Treatment System, Benvenue Medical, Santa Clara,
CA, USA), which received CE Mark approval in
December 2008. The Kiva
® System is a sterile, single-
use device in which an external delivery handle is used
to deploy the Kiva
® implant over a nitinol coil guide-
wire. The coil is first advanced through the deploy-
ment cannula (Figure 1a) and into the cancellous
portion of the vertebral body (Figure 1b) using an
external handle. The Kiva
® implant, which is com-
prised of PEEK-OPTIMA
® (Invibio Inc., West Consho-
hocken, PA, USA) and loaded with 15% barium sulfate
to enhance visibility under fluoroscopy, is incremen-
tally advanced over the coil (Figure 1c) to form a nest-
ing, cylindrical column with an in situ outer diameter
of 20 mm. Up to four loops of the implant may be
inserted into the vertebral body for a maximum coil
stack height of 12 mm, which re-elevates the endplate,
thereby providing the desired vertebral fracture reduc-
tion (Figure 1d). After the coil is retracted, radiopaque
PMMA cement (2.5-4 cc per level) is injected through
the lumen of the implant, thereby interlocking the
implant to the vertebral body cancellous bone (Figures
2a and 2b). Percutaneous radiofrequency was applied
immediately before implant deployment in patients
with metastasis and myeloma.
A
B
C
D
Figure 1 Intraoperative fluoroscopic images of the Kiva
® VCF
Treatment System consisting of a percutaneously introduced
nitinol coil guidewire advanced through a deployment cannula
(a) and then fully coiled within the cancellous portion of the
fractured vertebral body (b). A radiopaque PEEK Implant is
delivered incrementally over the removable guidewire (c) in a
continuous loop to form a nesting, cylindrical column providing
vertical displacement that results in endplate re-elevation and
fracture reduction (d).
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Patient outcomes were evaluated pre-treatment and at
the 2- and 6-month follow-up visits. Patient-reported
back pain was quantified using an 11-point (0 to 10)
numeric scale. Back-specific functional disability was
self-reported with the Oswestry Disability Index (ODI)
(version 2) on a 0 to 100% scale [21]. Postoperative
cement extravasation and device-related adverse events
were assessed with computed tomography and plain
radiographs.
Data Analysis
Data were analyzed using Predictive Analytics Software
(v. 18, SPSS, Inc., Chicago, IL). Continuous data were
reported as mean ± standard deviation and categorical
data were reported as frequencies and percentages.
Longitudinal changes in patient outcomes were analyzed
with repeated measures analysis of variance.
Results
No cases of intraoperative hypotension, respiratory dis-
turbance, neurological deterioration, infection, or death
were observed and no blood transfusions were required.
There were 2 (4.8%) levels where anterior cement leak-
age was visible radiographically in patients with osteo-
lyses. No intracanal leakage was observed. No cases of
implant migration, subsidence, or refracture at the trea-
ted or adjacent levels were reported. Back pain scores
improved from 8.0 ± 1.6 at pre-treatment to 2.3 ± 1.0 at
2 months and 3.0 ± 1.5 at 6 months, representing a 71%
(p < 0.001) overall improvement. Back function similarly
improved from 64 ± 19% at pre-treatment to 28 ± 17%
at 2 months and 29 ± 19% at 6 months, representing a
56% (p < 0.001) overall improvement (Figure 3).
A
B
C
Figure 2 Preoperative lateral radiograph showing osteoporotic
vertebral compression fractures at L2 and L4 in a 72-year-old
female (a). Post-operative radiograph 6 months after treatment with
the Kiva
® VCF Treatment System demonstrating excellent vertebral
fracture reduction (b). Corresponding axial computed tomography
scan at 6 months illustrating excellent cement containment within
the implant at L2 (c).
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Figure 3 Improvement in back pain and function through 6
months following vertebral augmentation. Values are mean ±
95% confidence intervals. ODI: Oswestry Disability Index.
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The Kiva
® System is a novel, safe technique for percuta-
neous vertebral body augmentation in patients with
symptomatic osteoporotic fractures and osteolytic
metastases. In our initial experience with this device, we
demonstrated improvement in back pain and function
through 6 months post-treatment with no significant
procedural cement extravasation.
The results of this case series are encouraging. The
mean reduction in post-operative pain by 6 months was
approximately 5.0 units. These findings compare favor-
ably with the findings from four separate meta-analyses
of published studies of the clinical effectiveness of bal-
loon kyphoplasty. Specifically, the mean reductions
reported in these meta-analyses for post-operative pain
severity scores were 5.1 units from Bouza et al. [10], 5.6
units from Gill et al. [22], 5.4 units from Taylor et al.
[19], and 4.6 units from Eck et al. [20].
The effectiveness of vertebral augmentation remains
controversial especially since vertebroplasty was
reported to have only modest clinical benefit versus
sham in two randomized controlled trials [23,24]. These
studies enrolled patients with vertebral fracture ages of
less than 1 year. However, recent trials of vertebral aug-
mentation that enrolled patients with more acute frac-
tures (6 weeks to 3 months) have reported positive
results [17,18,25]. Therefore, the application of vertebral
augmentation techniques may be most beneficial when
applied soon after fracture, a concept that is in agree-
ment with the initial findings from the current series.
In kyphoplasty and vertebroplasty procedures, PMMA
cement may leak laterally to the soft tissues, superiorly
or inferiorly into the adjacent disc space, or posteriorly,
where it may involve the exiting nerve root or the spinal
canal [26]. The Kiva
® System, on the other hand, was
designed to reduce and stabilize osteoporotic vertebral
fractures by deploying a coiled PEEK implant which is
then augmented with cement. This technique allows
directional cement delivery, which helps to facilitate
cement containment. Our first experience with 42
implants confirmed that the Kiva
® System was able to
control cement leakage with only 2 (7.7%) observed
cases, none of which resulted in clinical sequelae. These
results compare favorably to cement leakage rates of 7
to 72% reported with kyphoplasty and vertebroplasty
[10,17-20].
Limitations of this feasibility study include lack of a
control group, a relatively short follow-up period, and
lack of objective measures of vertebral height restora-
tion. Despite these limitations, the initial clinical results
of this trial are promising and warrant further study in
larger series with longer follow-up periods.
Conclusions
The results from our initial clinical experience with the
Kiva
® VCF Treatment System demonstrated significant
improvements in back pain and function with minimal
and clinically insignificant procedural cement leakage.
Acknowledgements
We thank Mr. Randy Asher for graphical assistance.
Author details
1Orthopaedic Department, General Hospital “Agios Andreas”, 1 Tsertidou str,
26224 Patras, Greece.
2Miller Scientific Consulting, Inc., 422 Mountain Wasp
Drive, Biltmore Lake, NC 28715 USA.
3Jon E. Block, PhD, Inc., 2210 Jackson
Street, Suite 401, San Francisco, CA 94115 USA.
Authors’ contributions
PK and TR designed and conducted the study. LEM performed the statistical
analyses. LEM and JEB participated in data interpretation. All authors were
involved in drafting and critically revising the manuscript. All authors read
and approved the final manuscript.
Competing interests
LEM and JEB received financial support from Benvenue Medical (Santa Clara,
CA, USA) for manuscript development.
Received: 11 February 2011 Accepted: 22 September 2011
Published: 22 September 2011
References
1. Johnell O, Kanis JA: An estimate of the worldwide prevalence and
disability associated with osteoporotic fractures. Osteoporos Int 2006,
17(12):1726-1733.
2. Cook DJ, Guyatt GH, Adachi JD, Clifton J, Griffith LE, Epstein RS, Juniper EF:
Quality of life issues in women with vertebral fractures due to
osteoporosis. Arthritis Rheum 1993, 36(6):750-756.
3. Leech JA, Dulberg C, Kellie S, Pattee L, Gay J: Relationship of lung function
to severity of osteoporosis in women. Am Rev Respir Dis 1990,
141(1):68-71.
4. Schlaich C, Minne HW, Bruckner T, Wagner G, Gebest HJ, Grunze M,
Ziegler R, Leidig-Bruckner G: Reduced pulmonary function in patients
with spinal osteoporotic fractures. Osteoporos Int 1998, 8(3):261-267.
5. Silverman SL: The clinical consequences of vertebral compression
fracture. Bone 1992, 13(Suppl 2):S27-31.
6. Gold DT: The clinical impact of vertebral fractures: quality of life in
women with osteoporosis. Bone 1996, 18(3 Suppl):185S-189S.
7. Gold DT: The nonskeletal consequences of osteoporotic fractures.
Psychologic and social outcomes. Rheum Dis Clin North Am 2001,
27(1):255-262.
8. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A,
Benhamou L, Geusens P, Flowers K, et al: Risk of new vertebral fracture in
the year following a fracture. JAMA 2001, 285(3):320-323.
9. Lyritis GP, Mayasis B, Tsakalakos N, Lambropoulos A, Gazi S, Karachalios T,
Tsekoura M, Yiatzides A: The natural history of the osteoporotic vertebral
fracture. Clin Rheumatol 1989, 8(Suppl 2):66-69.
10. Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM: Efficacy and safety of
balloon kyphoplasty in the treatment of vertebral compression fractures:
a systematic review. Eur Spine J 2006, 15(7):1050-1067.
11. Gangi A, Guth S, Imbert JP, Marin H, Dietemann JL: Percutaneous
vertebroplasty: indications, technique, and results. Radiographics 2003,
23(2):e10.
12. Hadjipavlou AG, Tzermiadianos MN, Katonis PG, Szpalski M: Percutaneous
vertebroplasty and balloon kyphoplasty for the treatment of
osteoporotic vertebral compression fractures and osteolytic tumours. J
Bone Joint Surg Br 2005, 87(12):1595-1604.
13. Ledlie JT, Renfro MB: Kyphoplasty treatment of vertebral fractures: 2-year
outcomes show sustained benefits. Spine (Phila Pa 1976) 2006, 31(1):57-64.
Korovessis et al. BMC Musculoskeletal Disorders 2011, 12:206
http://www.biomedcentral.com/1471-2474/12/206
Page 4 of 514. Lieberman IH, Dudeney S, Reinhardt MK, Bell G: Initial outcome and
efficacy of “kyphoplasty” in the treatment of painful osteoporotic
vertebral compression fractures. Spine (Phila Pa 1976) 2001,
26(14):1631-1638.
15. Majd ME, Farley S, Holt RT: Preliminary outcomes and efficacy of the first
360 consecutive kyphoplasties for the treatment of painful osteoporotic
vertebral compression fractures. Spine J 2005, 5(3):244-255.
16. Rao RD, Singrakhia MD: Painful osteoporotic vertebral fracture.
Pathogenesis, evaluation, and roles of vertebroplasty and kyphoplasty in
its management. J Bone Joint Surg Am 2003, 85-A(10):2010-2022.
17. Klazen CA, Lohle PN, de Vries J, Jansen FH, Tielbeek AV, Blonk MC,
Venmans A, van Rooij WJ, Schoemaker MC, Juttmann JR, et al:
Vertebroplasty versus conservative treatment in acute osteoporotic
vertebral compression fractures (Vertos II): an open-label randomised
trial. Lancet 2010, 376(9746):1085-1092.
18. Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB,
Ranstam J, Eastell R, Shabe P, Talmadge K, Boonen S: Efficacy and safety of
balloon kyphoplasty compared with non-surgical care for vertebral
compression fracture (FREE): a randomised controlled trial. Lancet 2009,
373(9668):1016-1024.
19. Taylor RS, Fritzell P, Taylor RJ: Balloon kyphoplasty in the management of
vertebral compression fractures: an updated systematic review and
meta-analysis. Eur Spine J 2007, 16(8):1085-1100.
20. Eck JC, Nachtigall D, Humphreys SC, Hodges SD: Comparison of
vertebroplasty and balloon kyphoplasty for treatment of vertebral
compression fractures: a meta-analysis of the literature. Spine J 2008,
8(3):488-497.
21. Fairbank JC, Pynsent PB: The Oswestry Disability Index. Spine (Phila Pa
1976) 2000, 25(22):2940-2952; discussion 2952.
22. Gill JB, Kuper M, Chin PC, Zhang Y, Schutt R Jr: Comparing pain reduction
following kyphoplasty and vertebroplasty for osteoporotic vertebral
compression fractures. Pain Physician 2007, 10(4):583-590.
23. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C,
Graves S, Staples MP, Murphy B: A randomized trial of vertebroplasty for
painful osteoporotic vertebral fractures. N Engl J Med 2009,
361(6):557-568.
24. Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH,
Edwards R, Gray LA, Stout L, Owen S, et al: A randomized trial of
vertebroplasty for osteoporotic spinal fractures. N Engl J Med 2009,
361(6):569-579.
25. Rousing R, Hansen KL, Andersen MO, Jespersen SM, Thomsen K,
Lauritsen JM: Twelve-months follow-up in forty-nine patients with acute/
semiacute osteoporotic vertebral fractures treated conservatively or with
percutaneous vertebroplasty: a clinical randomized study. Spine (Phila Pa
1976) 2010, 35(5):478-482.
26. Mirovsky Y, Anekstein Y, Shalmon E, Blankstein A, Peer A: Intradiscal
cement leak following percutaneous vertebroplasty. Spine (Phila Pa 1976)
2006, 31(10):1120-1124.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/12/206/prepub
doi:10.1186/1471-2474-12-206
Cite this article as: Korovessis et al.: Initial clinical experience with a
novel vertebral augmentation system for treatment of symptomatic
vertebral compression fractures: A case series of 26 consecutive
patients. BMC Musculoskeletal Disorders 2011 12:206.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Korovessis et al. BMC Musculoskeletal Disorders 2011, 12:206
http://www.biomedcentral.com/1471-2474/12/206
Page 5 of 5